Clinical trials: sponsored by iOMEDICO AG
Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
- Trial name
- CHAPLIN (NCT03911219)
- Testing
- eHealth system support for symptom management via CANKADO
- Where
- 92 sites in Germany
- Volunteers
- 154 people
- Sponsor
- iOMEDICO AG
Carcinoma, Non-Small-Cell Lung
PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
The objectives of this study are to assess molecular testing, treatment patterns, and associated outcomes among patients with EGFR (Epidermal Growth Factor Receptor) mutation-positive locally advanced or advanced NSCLC (Non-Small…
- Trial name
- PANORAMA (NCT02777658)
- Where
- 73 sites in Germany
- Volunteers
- 169 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma
Evaluation of patient reported outcomes ( PRO) regarding typical ailments in the REAL LIFE Renal Cell Carcinoma population
- Trial name
- PROKidney (NCT02537743)
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- iOMEDICO AG
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Metastatic Pancreatic Cancer, NSCLC, Metastatic
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
- Trial name
- PROXie (NCT02983500)
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- iOMEDICO AG
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Lung Cancer
Tumour Registry Lung Cancer (TLK)
Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.
- Trial name
- NCT01192919
- Volunteers
- 2,500 people
- Sponsor
- iOMEDICO AG
Non Hodgkin Lymphoma, Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics.
- Trial name
- CONVENIENCE (NCT03619993)
- Testing
- On-body injector, Pre-filled syringe
- Where
- 48 sites in Germany
- Volunteers
- 404 people
- Sponsor
- iOMEDICO AG
Advanced Breast Cancer, HER2-positive Breast Cancer
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
This is a randomized, open-label, two-arm, phase III trial in Germany to investigate whether vinorelbine-based triple combination presents a less toxic treatment option than docetaxel-based triple combination in patients with…
- Trial name
- ATTILA (NCT03811418)
- Testing
- Trastuzumab, Pertuzumab, Vinorelbine
- Where
- Germany
- Sponsor
- iOMEDICO AG
CIPN in Adjuvant Colon Cancer Patients, CIPN in Adjuvant Breast Cancer Patients
Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy
The objective of this observational study is to evaluate the effectiveness of the dietary supplementation "OnLife" in improving signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adult patients who have…
- Trial name
- STEFANO (NCT03065478)
- Testing
- OnLife
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Swiss Medical Food AG
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Metastatic Breast Cancer
Non-interventional Study With Nab-Paclitaxel (Abraxane®)
The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.
- Trial name
- NABUCCO (NCT01689610)
- Where
- Germany
- Volunteers
- 705 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
- Trial name
- REVLIMID-NIS (NCT00911105)
- Where
- 20 sites in Germany
- Volunteers
- 101 people
- Sponsor
- iOMEDICO AG
Breast Cancer
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
This is a clinical trial with a molecularly stratified parallel cohort, single arm design to explore the efficacy and safety of BKM120 in combination with tamoxifen in patients with ER/PR-positive, HER2-negative breast cancer…
- Trial name
- PIKTAM (NCT02404844)
- Testing
- BKM120, Tamoxifen
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Essen
Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.
- Trial name
- MARC-2 (NCT01266837)
- Testing
- Everolimus
- Where
- 8 sites in Germany
- Volunteers
- 64 people
- Sponsor
- iOMEDICO AG
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
This is a clinical trial with a crossover design to determine patients' preference for capecitabine in combination with bevacizumab or everolimus in combination with exemestane for advanced breast cancer patients and to evaluate…
- Conditions
- Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- IMPROVE (NCT02248571)
- Testing
- Bevacizumab, Capecitabine, Everolimus
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- iOMEDICO AG
Pain
Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades
The SUPPORT trial is an open-label, prospective, randomized, national multicenter intervention study to evaluate the effectiveness of ethyl-2-cyanoacrylate versus the standard treatment of each institution on the pain intensity…
- Trial name
- SUPPORT (NCT01693159)
- Testing
- ECA, Standard topical treatment of the institution, e.g. Lotio
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor.
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Trial name
- FLIPPER (NCT01521715)
- Testing
- Pazopanib
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- iOMEDICO AG
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.
- Trial name
- VicTORia (NCT01520103)
- Testing
- Vinorebine, Everolimus, Vinorelbine
- Where
- Germany
- Volunteers
- 139 people
- Sponsor
- AIO-Studien-gGmbH